Fasting makes kinase inhibitors more effective, meaning that patients would have to use them for less time to achieve the same results. (Photo/Heike-Giesler)
Fasting in combination with chemotherapy has already been shown to kill cancer cells, but a pair of new studies in mice suggests that a less-toxic class of drugs combined with fasting may kill breast, colorectal and lung cancer cells equally well.
If shown to work in humans, this combination could replace chemotherapy and make fasting a potent component of a long-term strategy to treat cancer, according to senior author Valter Longo of USC.
Human clinical trials in the United States and Europe are already studying the effectiveness and safety of Longo’s strategy of cyclic fasting during cancer treatment.
Published today by the journal Oncotarget, the studies suggest that a low-toxicity drug combined with fasting, or a diet that mimics the effects of fasting, could be an alternative to chemotherapy. The studies are part of a multinational collaboration with the laboratories of Alessio Nencioni at University of Genova and of Lizzia Raffaghello at the G. Gaslini Institute in Italy.
Cancer cells are fairly inflexible about how they produce energy, which gives us a way to target them.
“Like every other cell, cancer cells need energy to survive and keep growing. But cancer cells are fairly inflexible about how they produce that energy, which gives us a way to target them,” said Longo, Edna M. Jones Professor of Biogerontology at the USC Davis School of Gerontology and director of the USC Longevity Institute. Longo has a joint appointment at the USC Dornsife College of Letters, Arts and Sciences.
Cancer cells on overdrive
Cancer cells rely heavily on glucose (sugar) from food for energy — they’re on overdrive, burning much more glucose than a regular cell to fuel their rapid growth. The phenomenon is called the Warburg effect, named after the German physician who first described it nearly 100 years ago. As such, cancer cells are much more vulnerable to any interruption in supply.
Deprived of glucose, cancer cells rely on an emergency backup — using a type of enzyme called a kinase to continue their growth-related activities.
Longo and his team and collaborators discovered that this metabolic shift by cancer cells causes them to generate toxic-free radicals, which ultimately kills them. In addition, the kinase pathway for generating energy can be blocked by kinase inhibitors, further choking off cancer cells’ ability to generate energy. Kinase inhibitors are already approved by the U.S. Food and Drug Administration as a cancer treatment, opening the door to using them and fasting as a one-two punch to knock out cancer.
“However, kinase inhibitors, though much less toxic than chemotherapy, can still be toxic to many cell types. Fasting makes them more effective, meaning that patients would have to use them for less time to achieve the same results,” Longo said. “Although we have not yet tested this, we anticipate that fasting will also reduce the toxicity of kinase inhibitors as it reduces that of chemotherapy to normal cells.”
Other researchers who played key roles in the studies are Giovanna Bianchi and Irene Caffa in Genoa, Italy. Researchers at the University of Genoa, the G. Gaslini Institute, USC Davis and the Keck School of Medicine of USC also participated.
The research was supported by the Associazione Italiana per la Ricerca sul Cancro (AIRC, #6108); the Seventh Framework project PANCREAS (#256986); the Compagnia di San Paolo (ROL 689); the Fondazione Umberto Veronesi; and the University of Genoa.